FDA Brief

Warning letters Drugs

FDA warning letter to

Lean Rx, Inc. dba SkinnyRx

LowIssued Feb 20Posted Mar 3Center for Drug Evaluation and Research (CDER)

SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.

What happened

FDA reviewed the website https://skinnyrx.com in December 2025 and saw that it offers compounded semaglutide and tirzepatide drug products. The pictured product labels carry the name "SkinnyRx," which FDA says wrongly suggests SkinnyRx is the compounder, and the site makes claims comparing the products to FDA-approved name-brand GLP-1 medicines. FDA says these statements are false or misleading, which makes the products misbranded.

What FDA found

  1. The website's product labels show "SkinnyRx" as if SkinnyRx made the drugs, but it does not, so the labeling is false or misleading.

    FDCA § 502(a) [21 U.S.C. § 352(a)]; 21 CFR § 201.1(h)(2)
  2. The website says the products are "from the same family as GLP-1 treatments like Mounjaro and Zepbound" and have "the same active ingredient as name-brand GLP-1 medications," which suggests they are FDA-approved when they are not.

    FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. Advertising for a compounded drug that is false or misleading in any way makes the drug misbranded.

    FDCA § 502(bb) [21 U.S.C. § 352(bb)]
  4. Sending these misbranded drugs, or delivering them for shipment, in interstate commerce is a prohibited act.

    FDCA § 301(a) [21 U.S.C. § 331(a)]
  5. Receiving misbranded drugs in interstate commerce, or delivering them, is also a prohibited act.

    FDCA § 301(c) [21 U.S.C. § 331(c)]

What FDA wants

Within 15 working days, SkinnyRx must send the Office of Compounding Quality and Compliance a written response describing the steps it has taken, naming the entities that actually make the products, providing sample labeling, and fixing or removing the misleading claims. If it cannot finish in that time, it must explain why and give a date.

Who should pay attention

  • telehealth companies that market compounded GLP-1 drugs
  • marketers and resellers that put their own name on product made by someone else
  • compounding pharmacies whose products are sold under another company's brand

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low